Myeloma Matters: Bispecific Antibody Horizons: Dosing Strategies and Meeting Updates in Myeloma Care

Project Oncology®

Host: Saad Z. Usmani, MD, MBA, FACP
Guest: Joshua Richter, MD
Guest: Ashley Steinberger, APP
Release date: 8/15/2024
Expiration date: 8/15/2025
Estimated time to complete: 1.0 hour

This activity is not accredited for CME/CE credit.

This episode of Myeloma Matters reviews the latest data on bispecific antibody therapy for relapsed/refractory multiple myeloma (RRMM) discussed at the 2024 American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) annual meetings, including information about the use of fixed-duration dosing to mitigate adverse events (AEs).

The program includes in-depth discussion and analysis of the latest scientific findings and practice-changing advances in managing RRMM. Expert faculty will place abstract findings into clinical context and discuss strategies for preventing and managing AEs associated with bispecific antibody therapy in RRMM treatment, which include cytokine release syndrome (CRS), neurotoxicity, and infection.